SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 185 filers reported holding SAGE THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $191,168 | -48.6% | 9,289 | +17.4% | 0.00% | -50.0% |
| Q2 2023 | $372,116 | +12.1% | 7,914 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $332,071 | +36.7% | 7,914 | +24.2% | 0.00% | +100.0% |
| Q4 2022 | $242,952 | -18.5% | 6,370 | -16.4% | 0.00% | -50.0% |
| Q3 2022 | $298,000 | +21.1% | 7,621 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $246,000 | -3.5% | 7,621 | -0.9% | 0.00% | 0.0% |
| Q1 2022 | $255,000 | -21.1% | 7,689 | +1.2% | 0.00% | -50.0% |
| Q4 2021 | $323,000 | +16.2% | 7,595 | +21.0% | 0.00% | 0.0% |
| Q3 2021 | $278,000 | -22.1% | 6,275 | -0.2% | 0.00% | 0.0% |
| Q2 2021 | $357,000 | -23.7% | 6,288 | +0.5% | 0.00% | -33.3% |
| Q1 2021 | $468,000 | -19.2% | 6,254 | -6.6% | 0.00% | -25.0% |
| Q4 2020 | $579,000 | +31.0% | 6,696 | -7.4% | 0.00% | +33.3% |
| Q3 2020 | $442,000 | +46.8% | 7,232 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $301,000 | +152.9% | 7,232 | +74.7% | 0.00% | +200.0% |
| Q1 2020 | $119,000 | -51.2% | 4,139 | +22.7% | 0.00% | -50.0% |
| Q4 2019 | $244,000 | -48.4% | 3,374 | 0.0% | 0.00% | -50.0% |
| Q3 2019 | $473,000 | -21.0% | 3,374 | +3.1% | 0.00% | -20.0% |
| Q2 2019 | $599,000 | +21.3% | 3,271 | +5.3% | 0.01% | +25.0% |
| Q1 2019 | $494,000 | +75.8% | 3,106 | +6.0% | 0.00% | +33.3% |
| Q4 2018 | $281,000 | -32.1% | 2,931 | 0.0% | 0.00% | -25.0% |
| Q3 2018 | $414,000 | -2.6% | 2,931 | +8.0% | 0.00% | 0.0% |
| Q2 2018 | $425,000 | -6.6% | 2,715 | -4.0% | 0.00% | 0.0% |
| Q1 2018 | $455,000 | +33.0% | 2,827 | +36.0% | 0.00% | +33.3% |
| Q4 2017 | $342,000 | +297.7% | 2,078 | +50.8% | 0.00% | +200.0% |
| Q3 2017 | $86,000 | -21.8% | 1,378 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $110,000 | +25.0% | 1,378 | +11.1% | 0.00% | 0.0% |
| Q1 2017 | $88,000 | +39.7% | 1,240 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $63,000 | +90.9% | 1,240 | +74.6% | 0.00% | – |
| Q3 2016 | $33,000 | +94.1% | 710 | +24.8% | 0.00% | – |
| Q2 2016 | $17,000 | -5.6% | 569 | 0.0% | 0.00% | – |
| Q1 2016 | $18,000 | -45.5% | 569 | 0.0% | 0.00% | – |
| Q4 2015 | $33,000 | +371.4% | 569 | +264.7% | 0.00% | – |
| Q3 2015 | $7,000 | – | 156 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |